Relapsed Refractory Chronic Lymphocytic Leukemia Relapsed Refractory Small Lymphocytic Leukemia clinical trials

Explore recruiting relapsed refractory chronic lymphocytic leukemia relapsed refractory small lymphocytic leukemia clinical trials.

Recruiting relapsed refractory chronic lymphocytic leukemia relapsed refractory small lymphocytic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Chronic Lymphocytic Leukemia Relapsed Refractory Small Lymphocytic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Spain, Belgium, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Relapsed Refractory Chronic Lymphocytic Leukemia Relapsed Refractory Small Lymphocytic Leukemia trials by city

Relapsed Refractory Chronic Lymphocytic Leukemia Relapsed Refractory Small Lymphocytic Leukemia clinical trials

Recruiting relapsed refractory chronic lymphocytic leukemia relapsed refractory small lymphocytic leukemia studies right now

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Also recruiting in Europe

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Relapsed Refractory Chronic Lymphocytic Leukemia Relapsed Refractory Small Lymphocytic Leukemia trials by city

Other conditions